Pancreatic Cancer Research

ResearcherUniversity of ZurichActive in the last 2 years

Dilmurodjon Eshmuminov

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9575-7094; OpenAlex author ID A5034789424. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
51
Papers, trials and grants by year

2022: 1 paper · 2023: 2 papers · 2024: none · 2025: none · 2026: 4 papers

Papers 7

  1. Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis. Last author DOI 10.1093/jnci/djag235↗
  2. Benefit of Adjuvant Therapy After Neoadjuvant Therapy and Resection for Patients with Pancreatic Cancer: A Systematic Review and Meta-analysis. Last author DOI 10.1245/s10434-026-19841-5↗
  3. ASO Visual Abstract: Benefit of Adjuvant Therapy after Neoadjuvant Therapy and Resection for Patients with Pancreatic Cancer: A Systematic Review and Meta-anal… Last author DOI 10.1245/s10434-026-19926-1↗
  4. ASO Author Reflections: Beyond Neoadjuvant Therapy in Pancreatic Cancer-Why Adjuvant Therapy Still Matters After Neoadjuvant Treatment. First author DOI 10.1245/s10434-026-19965-8↗
  5. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analy… Co-author DOI 10.1245/s10434-023-13353-2↗
  6. ASO Author Reflections: Chemotherapy Regimen in Borderline Resectable and Locally Advanced Pancreatic Cancer-Resection Cuts the Deal. Co-author DOI 10.1245/s10434-023-13484-6↗
  7. De novo expression of gastrokines in pancreatic precursor lesions impede the development of pancreatic cancer. Co-author DOI 10.1038/s41388-022-02182-4↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael C. Frey · 4 shared papers, 2026 · strength 1.32
  2. Víctor López‐López · 4 shared papers, 2023–2026 · strength 0.81
  3. Changhoon Yoo · 4 shared papers, 2023–2026 · strength 0.81
  4. José Oberholzer · 3 shared papers, 2026 · strength 0.69
  5. Ning Pu · 3 shared papers, 2026 · strength 0.69
  6. So Heun Lee · 3 shared papers, 2026 · strength 0.69
  7. Ralph Fritsch · 3 shared papers, 2026 · strength 0.69
  8. Russell F. Palm · 3 shared papers, 2023–2026 · strength 0.57
  9. Bradley Norman Reames · 2 shared papers, 2026 · strength 0.50
  10. Haleh Amirian · 2 shared papers, 2026 · strength 0.50
  11. Chunmeng Zhang · 2 shared papers, 2026 · strength 0.50
  12. Jashodeep Datta · 2 shared papers, 2026 · strength 0.50
  13. Kuno Lehmann · 2 shared papers, 2023 · strength 0.38
  14. Giuseppe Malleo · 2 shared papers, 2023–2026 · strength 0.31
  15. Gregory C. Wilson · 2 shared papers, 2023–2026 · strength 0.31
  16. Ryan K. Schmocker · 2 shared papers, 2023–2026 · strength 0.31
  17. Jin Peng He · 2 shared papers, 2023–2026 · strength 0.31
  18. Elena B. Rangelova · 2 shared papers, 2023–2026 · strength 0.31
  19. Sarah E. Hoffe · 2 shared papers, 2023–2026 · strength 0.31
  20. Sameer H. Patel · 2 shared papers, 2023–2026 · strength 0.31
  21. Syed A. Ahmad · 1 shared paper, 2026 · strength 0.19
  22. Liang Liu · 1 shared paper, 2026 · strength 0.19
  23. Patricia Sánchez‐Velázquez · 1 shared paper, 2026 · strength 0.19
  24. Benedetto Ielpo · 1 shared paper, 2026 · strength 0.19
  25. Gabriella Lionetto · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.